Live Breaking News & Updates on Carmen Escuriola Ettingshausen
Stay updated with breaking news from Carmen escuriola ettingshausen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
LACHEN, Switzerland, June 6, 2023 /PRNewswire/ Octapharma to present new clinical and scientific findings for wilate®, Nuwiq®, octaplex® and atenativ® at the upcoming ISTH 2023 CongressNew ....
/PRNewswire/ Octapharma to present new clinical and scientific findings for wilate®, Nuwiq®, octaplex® and atenativ® at the upcoming ISTH 2023 Congress New. ....
/PRNewswire/ Replacement therapy with factor VIII has been the mainstay of care for patients with severe haemophilia A for over 30 years, with proven. ....
Share this article Share this article ATLANTA, May 28, 2021 /PRNewswire/ Dr Robert Sidonio and Dr Carmen Escuriola-Ettingshausen have announced that MOTIVATE (MOdern Treatment of Inhibitor-positiVe pATiEnts with haemophilia A) has commenced patient enrollment in the US. MOTIVATE is a multicenter, investigator-initiated study aiming to capture different approaches used for the management of patients with hemophilia A and inhibitors. It is registered as a non-interventional study in the US (NCT04023019) and as a low-interventional, pragmatic trial in Europe (EudraCT No. 2019-003427-38). Dr Sidonio, Coordinating Investigator of the study for the US and Canada, commented that We are very excited that patient enrollment in MOTIVATE has begun in the US. The data being collected will be invaluable in progressing our understanding of the efficacy and safety of different therapeutic regimens, bringing us closer to our goal of improving the standard of care for hemophilia ....
MOTIVATE (MOdern Treatment of Inhibitor-positiVe pATiEnts with haemophilia A) enrolls first patient in the US streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.